Expertise in
5
conditions

Liqun P. Zou

Chengdu, CN 
Expertise in
5
conditions
Chengdu, CN 

Overview

Liqun Zou practices practicing medicine in Chengdu, China.

Zou is highly rated in 5 conditions, according to our data. Their clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, and Peripheral T-Cell Lymphoma.

They are actively involved in clinical research, co-authoring 134 peer reviewed articles and participating in 4 clinical trials.

Locations

Chengdu, China
Other Locations
Shanghai Key Laboratory Of Functional Materials Chemistry, Shanghai, 200237, China
Zhuhai, 519082, China
Guangdong Provincial Key Laboratory Of Chinese Medicine Pharmaceutics, Guangzhou, 510515, China
China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients With Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug
Study Drug: HMPL-689
Study Phase: Phase 2
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
An Open-label and Single Arm Study of ATG-010 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: ATG-010
Study Phase: Phase 2
An Open, Single-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib SandwichWith Radiotherapy in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma
An Open, Single-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib SandwichWith Radiotherapy in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug
Study Drug: Sintilimab
Study Phase: Phase 2
View 3 Less Clinical Trials

134 Total Publications

Comparative effectiveness and safety of biliary drainage strategies for malignant biliary obstruction: a protocol for systematic review and network meta-analysis.
Comparative effectiveness and safety of biliary drainage strategies for malignant biliary obstruction: a protocol for systematic review and network meta-analysis.
Journal: BMJ open
Published: August 13, 2026

Frequently Asked Questions about Liqun P. Zou

Is Liqun P. Zou a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Liqun P. Zou is classified as an Advanced expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Liqun P. Zou participate in research or clinical trials?

Yes. Liqun P. Zou has published 134 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Liqun P. Zou's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zou's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile